GLTO

#11856
Damora Therapeutics, Inc. Common Stock
28.69 USD
-0.76%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
28.69
28.69
Rango anual
2.01
38.33
Cambio diario
-0.76%
Variación mensual
-6.00%
Variación en los últimos 6 meses
+917.38%
Cambio anual
+613.68%
Cierres anteriores
28.91
Abrir
28.69
Bid
Ask
Mínimo
28.69
High
28.69
Volumen
10
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 1.59 B
  • Employee 7
  • Founded 2011
  • CEO Hans T. Schambye
  • Website www.damoratx.com
  • Headquarter Delaware, United States
  • FIGI BBG00XMLGWC5
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-5.78
Relación precio/flujo de caja
28.96

Galecto Inc

Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark. The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need.

Noticias